Clene to Present at the Emerging Growth Conference
Rhea-AI Summary
Clene (NASDAQ: CLNN), a clinical-stage biopharmaceutical company focused on neurodegenerative disease treatments, will present at the upcoming Emerging Growth Conference. The virtual presentation is scheduled for August 20, 2025, at 2:20 p.m. ET.
The corporate update will include a Q&A session and will be accessible through a webcast on Clene's website. A replay will be available through the conference portal and the Emerging Growth YouTube Channel after the event.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, CLNN declined 1.35%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
SALT LAKE CITY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Emerging Growth Conference.
Virtual Presentation Details
Date: August 20, 2025
Time of Presentation: 2:20 p.m. ET
Format: Corporate update with Q&A
A webcast of the presentation will be available on the “Events” section of the Clene website. Alternatively, one can register for and view the webcast, along with accompanying slides, here: https://goto.webcasts.com/starthere.jsp?ei=1717088&tp_key=22f1f30884&sti=clnn. A replay of the presentation will also be available through the conference portal and the Emerging Growth YouTube Channel, http://www.YouTube.com/EmergingGrowthConference, following the event.
About the Emerging Growth Conference
The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.
The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.
All sessions will be conducted through video webcasts and will take place in the Eastern time zone.
About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.
| Investor Contact Kevin Gardner LifeSci Advisors kgardner@lifesciadvisors.com 617-283-2856 |
FAQ
When is Clene (CLNN) presenting at the Emerging Growth Conference?
How can investors access Clene's (CLNN) Emerging Growth Conference presentation?
What is Clene's (CLNN) main focus as a company?
What type of presentation will Clene (CLNN) deliver at the conference?
